Sugi Predict

Sugi Predict / Compounds / SCHEMBL130906

SCHEMBL130906

SCHEMBL130906

O=C(O)c1cc(N=Nc2ccccc2S(=O)(=O)Nc2ccccn2)ccc1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A11 Q9UPY5 3/20 0.76
▸ MEN1 O00255 2/20 0.76
▸ BLVRB P30043 2/20 0.76
▸ KMT2A Q03164 2/20 0.76
▸ ABCC3 O15438 1/20 0.76
▸ ABCC4 O15439 1/20 0.76
▸ USP2 O75604 1/20 0.76
▸ SLCO2B1 O94956 1/20 0.76
▸ ALDH1A1 P00352 1/20 0.76
▸ CA1 P00915 1/20 0.76
▸ CA2 P00918 1/20 0.76
▸ LMNA P02545 1/20 0.76
▸ MMP1 P03956 1/20 0.76
▸ ABCB1 P08183 1/20 0.76
▸ MAPT P10636 1/20 0.76
▸ CYP2C9 P11712 1/20 0.76
▸ HPGD P15428 1/20 0.76
▸ TSHR P16473 1/20 0.76
▸ NFKB1 P19838 1/20 0.76
▸ TBXAS1 P24557 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9286174 0.92 SLC7A11 (0.63) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL4515 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL29861725 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL18256143 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL487664 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL10289061 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL31174674 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL4514 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL5664970 0.86 SLC7A11 (1.00) SLC7A11MEN1BLVRBKMT2AABCC3
Sulfasalazine SCHEMBL21055748 0.85 SLC7A11 (0.98) SLC7A11MEN1BLVRBKMT2AABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 — — US disclosed
CN-101849953-B Inflammatory cytokine release inhibitor INST MED MOLECULAR DESIGN INC 2012-04-25 — — CN disclosed
EP-1844766-B1 Inhibitors against the production and release of inflammatory cytokines INST MED MOLECULAR DESIGN INC (JP) 2012-04-18 — — EP disclosed
EP-1352650-B1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES INST MED MOLECULAR DESIGN INC (JP) 2012-03-07 — — EP disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 — — US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 — — US disclosed
CN-101849953-A Inflammatory cytokine release inhibitor INST MED MOLECULAR DESIGN INC 2010-10-06 — — CN disclosed
CN-1658872-B Antiallergic agent INST MED MOLECULAR DESIGN INC 2010-09-22 — — CN disclosed
US-7700655-B2 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-04-20 — — US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 — — US disclosed
EP-1535610-A1 THERAPEUTIC AGENT FOR CANCER Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 — — EP disclosed
EP-1535609-A1 NF-KB ACTIVATION INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 — — EP disclosed
EP-1514544-A1 ANTIALLERGIC Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-16 — — EP disclosed
EP-1512396-A1 INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 — — EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 — — US disclosed
CN-1489458-A Inflammatory cytokine production dissociation inhibitor ��ʽ����ҽҩ��������о��� 2004-04-14 — — CN disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 — — EP disclosed
US-6613784-B1 Cyclooxygenase inhibitors such as 2-acetyloxybenzoic acid 6-(nitroxymethyl)-2-methylpyridinyl ester hydrochloride, having good kinetics, solubility and efficiency; nontoxic NICOX S.A. (FR) 2003-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A SLC7A11 3035/4885MEN1 4495/4885BLVRB 3448/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A SLC7A11 3044/4885MEN1 4504/4885BLVRB 3214/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB SLC7A11 3283/4885MEN1 4661/4885BLVRB 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.